Rein Therapeutics shares are trading lower. The company issued an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis.

Benzinga Newsdesk www.benzinga.com Neutral 61.8%

Neg 0% Neu 61.8% Pos 0%

Comments

No comments yet. Be the first!